3-way competition among Boehringer, Astra & MSD over new antidiabetic complexes
In the Korean diabetes treatment market, a 3-way competition is expected among complexes in combination with DPP-4 and SGLT-2 inhibitors.
According to MSD, ‘ertugliflozin,’ a SGLT-2 inhibitor jointly being developed by MSD and Pfizer, was confirmed to drop down blood sugar when additionally admi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
